Distinct progression patterns of brain disease in infantile and juvenile gangliosidoses: Volumetric quantitative MRI study.
Igor Nestrasil, Alia Ahmed, Josephine M Utz...
https://pubmed.ncbi.nlm.nih.gov/29352662/Actively Recruiting
Led by University of Minnesota · Updated on 2026-03-04
52
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are studying the natural history and progression of gangliosidosis diseases, including Tay-Sachs disease, Sandhoff disease, and GM1 gangliosidosis. The study aims to develop quantitative methods to understand how these diseases evolve and vary among patients. This information will be important for evaluating future treatments like gene therapy, guiding medical decisions, measuring treatment outcomes, and informing families about potential disease outcomes. The study includes two main parts. The first part follows infants and juveniles with these diseases to observe how their condition changes over time. The second part focuses on adults with late-onset Tay-Sachs disease, using brain imaging and cognitive tests to study nervous system changes. Participants will be observed over multiple years to collect detailed data on their disease progression. Participants will undergo neuropsychological tests, brain MRIs, enzyme activity measurements, genetic testing, and clinical assessments at enrollment and then at 12, 24, 36, 48, and 60 months. The study collects detailed information on brain structure, cognitive status, and biochemical markers to track disease changes. This observational study lasts several years, with ongoing monitoring to better understand these rare conditions and support future treatment development.
CONDITIONS
A Natural History Study of the Gangliosidoses
J
Jeanine R. Jarnes, PharmD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Minnesota
Lead Sponsor
Rare Diseases Clinical Research Network
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years
Participants undergo ongoing assessments to observe the progression of gangliosidosis diseases over time.
Visits at enrollment and at 12, 24, 36, 48, and 60 months
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Igor Nestrasil, Alia Ahmed, Josephine M Utz...
https://pubmed.ncbi.nlm.nih.gov/29352662/R Navon, Z Argov, A Frisch
https://pubmed.ncbi.nlm.nih.gov/2939718/M Kaback, J Lim-Steele, D Dabholkar...
https://pubmed.ncbi.nlm.nih.gov/8230592/C M Zaroff, O Neudorfer, C Morrison...
https://pubmed.ncbi.nlm.nih.gov/15210895/Orit Neudorfer, Gregory M Pastores, Bai J Zeng...
https://pubmed.ncbi.nlm.nih.gov/15714079/Jeanine R Jarnes Utz, Sarah Kim, Kelly King...
https://pubmed.ncbi.nlm.nih.gov/28476546/Jeanine R Jarnes Utz, Thomas Crutcher, Joseph Schneider...
https://pubmed.ncbi.nlm.nih.gov/25557439/G M MacQueen, P I Rosebush, M F Mazurek
https://pubmed.ncbi.nlm.nih.gov/9547461/Lauren C Frey, Steven P Ringel, Christopher M Filley
https://pubmed.ncbi.nlm.nih.gov/15956171/University of Minnesota
Lead Sponsor
Rare Diseases Clinical Research Network
Collaborating Sponsor